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Abstract:  Astrogliosis  is  a  pathological  process  which  affects  the
density, morphology and function of astrocytes. It is a common feature
of  brain  trauma,  autoimmune  diseases  and  neurodegeneration
including spinocerebellar  ataxia type 1 (SCA1),  a poorly  understood
neurodegenerative disease. S100β is a Ca2+ binding protein. In SCA1,
excessive excretion of S100β by reactive astrocytes and its uptake by
Purkinje cells has been demonstrated previously. Under pathological
conditions, excessive extracellular concentration of S100β stimulates
production  of  proinflammatory  cytokines and induces  apoptosis.  We
modeled astrogliosis by S100β injections into cerebellar cortex in mice.
Injections of S100β led to significant changes in Bergmann glia cortical
organization  and  affected  their  processes.  S100β  also  changed
morphology of the Purkinje cells (PCs), causing a significant reduction
of the dendritic  length.  Moreover,  the short-term synaptic  plasticity
and depolarization-induced suppression of synaptic transmission, were
disrupted after S100β injections. We speculate that these effects are
due  to  Ca2+-chelating  properties  of  S100β  protein.  In  summary,
exogenous  S100β  induced  astrogliosis  in  cerebellum  could  lead  to
neuronal  dysfunction  which  resembles  a  natural  neurodegenerative
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process. We suggest that astrocytes are playing an essential role in
SCA1pathology  and astrocytic  S100β  is  an important  contributor  to
this process.
Keywords:  astrocytes;  S100β;  Purkinje  cells;  short  term  plasticity;
Ca2+ signaling
1. Introduction
Spinocerebellar  ataxia  type  1  (SCA1)  is  a  progressive
neurodegenerative  hereditary  disorder  which  affects  mainly  the
cerebellum and brainstem. It is caused by a dynamic expansion of CAG
repeats  in  the  N-terminal  coding  region  of  geneATXN1  gene  on
chromosome 6p23 [1, 2]. In general population, prevalence of SCA1 is
only 1-2 per 100 000, but in specific ethnic groups this ratio varies [3].
SCA1 is characterized by progressive cerebellar dysfunction, dysarthria
and  worsening  of  bulbar  functions.  Pathological  changes  include
neuronal  loss  in  the  cerebellum,  brainstem,  and  degeneration  of
spinocerebellar  tracts  [4,  5].  Higher  cortical  functions  may  also  be
affected with symptoms including memory loss, verbal and nonverbal
intellectual  deficits  [6].  CAG  repeats  encode  amino  acid  glutamine;
therefore their expansion leads to synthesis of Ataxin 1 with excessive
polyglutamine  tract.  This  affects  protein  folding  and  leads  to
precipitation  as  intracellular  aggregates  [7,  8].  The  aggregates  also
contain inclusions of ubiquitin, proteasome components and chaperons
[9].  In  SCA1  mouse  model  aggregation  occurs  later  than  the  first
pathological  sights  appear  and  does  not  correlate  with  the  disease
severity  [10].  Accumulation  of  the  mutant  protein  leads  to  selective
neurodegeneration  in  certain  regions  of  the  brain  and  reactive
astrocytosis.  Astrogliosis  in SCA1 is tightly correlated with the onset
and severity of disease and is  not a consequence of neuronal  death.
Cvetanovic et al. (2015) described the astrocytic and microglial reaction
in SCA1,  using  non-cell  selective SCA1 knock-in (Sca1154Q/2Q)  and PC
selective B05 SCA182Q/2Q mouse models.  They showed that  astrocytes
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and  microglia  are  activated  at  early  stages  of  SCA1.  Expression  of
protein  Ataxin 1 in microglia and astrocytes was not essential for the
activation of glia but expression in Purkinje cells was sufficient for it
[11, 12].
In cerebellum, reactive astrogliosis of Bergmann glia may disrupt the
spatial distribution of EAAT1 (Excitatory Amino Acids Transporter 1 or
Glutamate  Aspartate  Transporter  (GLAST)).  This  could  result  in  an
increase  in  extracellular  glutamate  concentrations  and  toxicity  via
NMDA-receptors  [12,  13].  In  addition,  activated  astrocytes  and
microglia are able to release various proinflammatory molecules. Some
of them, such as Tumor Necrosis Factor α (TNFα), interleukin-6 (IL6)
and monocyte chemoattractant protein-1 (MCP-1) have been implicated
in neurodegeneration and negatively affect the function and survival of
neurons [14–19]. S100β protein is one of the S100 Ca2+-binding proteins
of  the  S100  group  which  includes  nearly  20  members  [20].  S100
proteins form homo- and heterodimers and are able to chelate not only
Ca2+,  but  also  Zn2+ and  Сuu2+ [21].  Binding  of  the  ions  changes  the
confirmation of S100 and alters their affinity to different ligands (more
than 90 potential targets known currently) [20–23].
Here we model astrogliosis in cerebellum, such as seen in SCA1, by the
intracortical injections of S100β. We demonstrate a significant negative
impact of this astrocytic protein to the PCs morphology and synaptic
transmission  in  the  parallel  fibre-Purkinje  cell  (PF-PC)  synapse.
Moreover,  we  demonstrate  that  short  term  synaptic  plasticity,  the
depolarization-induced suppression of excitation (DSE) is disrupted by
S100β. We speculate that these effects could be attributed to the Ca2+-
chelating properties of S100β.
2. Materials and Methods
All procedures for the care and treatment of animals were carried
out according to the Krasnoyarsk State Medical University and Russian
public  standard  (33215-2014)  regulations  and  approved by  the  local
ethical committee. Every effort was made to minimize animal suffering
and to reduce the number of animals used in this study. 12 weeks old
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CD-1 IGS WT mice (Charles River Laboratories) were used in this study.
4 weeks old non-cell selective SCA1154Q/2Qknock-inn(SCA1 KI) mice with
C57BL/6J background used in this work [24]. Experiments with SCA1 KI
mice  were  generated  in  Gunma  University  (Japan)  in  laboratory  of
Neurophysiology and Neuronal Repairled by Professor H. Hirai. These
were mice kindly provided by Dr. Hidehiro Mizusawa (Tokyo Medical
and Dental University). Animals were kept on a 12-h light/dark cycle
with free access to food and water. 
2.1. Drugs and reagents
All  reagents for electrophysiological experiments  were from Sigma
Aldrich.
Recombinant mouse S100 Calcium Binding Protein B (S100β) (Cat.
No. APA567Mu01) was obtained from Cloud-Clone Corp. Concentrated
stock  solution  of  S100β  was  initially  prepared  and  diluted  in
physiological  saline  (PBS)  to  a  final  concentration  before  use.
Fluorocitrate (FC) was used as barium salt (Cat. F9634, Sigma Aldrich)
as  described  previously  (Paulsen  et  al.,  1987).  (3S)-3-[[3-[[4-
(Trifluoromethyl)benzoyl]amino]phenyl]methoxy]-L-aspartic  acid  (TFB-
TBOA) (Cat. No. 2532) was obtained from Tocris. Concentrated stock
solutions of FCand TBOA were initially prepared and diluted in artificial
spinocerebellar fluid (ACSF) to their final concentrations before use.
2.2. S100β injections
12-week-old  (P90-P100)  WT  CD1  mice  were  anaesthetized  by
intraperitoneal injection of chloral hydrate solution (400mg/kg of body
weight).  2,5μl of 50μM S100β in phosphate buffered saline (PBS) orl  of  50μl of 50μM S100β in phosphate buffered saline (PBS) orM S100β in phosphate buffered saline (PBS) or
PBS was  stereotaxically  injected into the cortex of cerebellar  vermis
(lobule VI) using 10μl of 50μM S100β in phosphate buffered saline (PBS) orl Hammilton syringe. To reach the injection point
in the vermis we used the coordinates relative to bregma: AP: -2,5 mm,
ML: 0 mm, DV: 2mm.Mice were used 24 hours after the injection.
2.3. Electrophysiology
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Cerebellar  slices  (250  μl of 50μM S100β in phosphate buffered saline (PBS) orm  thick)  were  prepared,  and  whole-cell
recordings were conducted as described previously [25]. Briefly, mice
were deeply anesthetized by intraperitoneal injection of chloral hydrate
(400mg/kg of body weight) and killed by decapitation. The brain was
quickly  dissected and placed for  one  minute  in  an  ice-cold  Ringer’s
solution containing: 234  mM sucrose, 26  mM NaHCO3, 2.5  mM  KCl,
1.25 mM NaH2PO4, 11 mM glucose, 10 mM MgSO4, and 0.5 mM CaCl2
0.5;  pH  7.4,  continuously  oxygenated  with  95%  O2  and  5%  CO2.
Parasagittal slices of cerebellar vermis were made using a microslicer
(Thermo Scientific; Microtom CU65). The slices were maintained in an
extracellular  solution containing:  125  mM  NaCl,  2.5  mM  KCl,  2  mM
CaCl2, 1 mM MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM D-
glucose, and 0.05-0.1 mM picrotoxin bubbled by 95% O2 /5% CO2 gas
mix at room temperature for 1h before starting the electrophysiological
experiments.  For  current  clamp  whole-cell  recordings  from  Purkinje
cells (PCs) we used K-gluconate-based intracellular solution containing:
130 mM K-gluconate, 4 mM KCl, 20 mM HEPES, 1 mM MgCl2, 4 mM
MgATP, 1 mM NaGTP, 0.4 mM EGTA (pH 7.3 adjusted with KOH). For
voltage clamp whole-cell recordings from Purkinje cells (PCs) we used
intracellular solution containing: 140 mM Cs-gluconate, 8 mM KCl, 10
mM HEPES,  1  mM MgCl2,  2  mM  MgATP,  0.4  mM  NaGTP,  0.4  mM
EGTA (pH 7.3 adjusted with CsOH). Passive electrical properties of the
PCs were estimated using averaged traces of ~10 current responses to
hyperpolarising voltage pulses (from -70 to -80 mV, 200 ms duration).
Fast  capacitance  component  was  automatically  compensated;  signal
was sampled at 50 kHz and low-pass filtered at 10 kHz. No correction
was made for liquid junction potentials. Analysis of electrophysiological
data was performed using pClamp10 (Molecular Devices), Pachmaster
software (HEKA), and Clampfit 10.5 (Axon instruments).
PCs were voltage-clamped at -70 mV to record PF EPSCs. Selective
stimulation of PFs was confirmed by paired-pulse facilitation of EPSC
amplitudes (at a 50-ms interstimulus interval).
To examine depolarization induced suppression of excitation (DSE),
PF EPSCs were recorded every 3 s. After monitoring basal PF EPSCs
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for 1 min, a single depolarizing pulse (5s from -70 to 0 mV) was applied
to the recorded PC. This opens the voltage gated Ca2+ channels (VGCC)
and  releases  endocannabinoids  which  presynaptically  decrease
glutamate release and suppress amplitude of PF EPSC [26]. Amplitudes
of  subsequent  PF  EPSCs  were  normalized  to  the  mean value  of  12
responses evoked before the induction of DSE.
2.4. Immunohistochemistry
For immunohistochemistry (IHC), anesthetized mice were perfused
transcardially  with 4% paraformaldehyde in  0.1  M phosphate buffer.
The brain was postfixed in the same fixative overnight. The cerebellar
vermis was cut into 50-µm sagittal sections. The sections were treated
with rabbit monoclonal anti-calbindin D-28 k (1:500, Cloud Clone Corp.,
China), chicken polyclonal anti-GFAP antibodies (1:1000, Abcam, UK),
rabbit  polyclonal  anti-S100β  (1:1000,  Abcam,  UK).  Secondary
antibodies  were  Alexa  Fluor  514-conjugated  donkey  anti-rabbit  IgG
(1:1,000, Life Technologies), Alexa Fluor 647-conjugated donkey anti-
chicken  IgG  (1:1,000,  Life  Technologies)  and  Alexa  Fluor  488-
conjugated  donkey  anti-rabbit  IgG  (1:1,000,  Life  Technologies).
Antibodies were dissolved in PBS solution containing 2% (v/v) normal
donkey serum, 0.1% (v/v) Triton X-100, and 0.05% NaN3. 
2.5 Confocal microscopy and morphometric analysis
Fluorescent images were obtained using confocal microscope  and
original  software  of  Olympus,  Fluoview,  FV10i  (Japan). Images  were
recorded as Z-stacks of 0.25 μl of 50μM S100β in phosphate buffered saline (PBS) orm thickness with  x10 lense,  numerical
aperture of 1.0,  zoom x6, at  1024x1024 resolution.  In all  groups the
cerebellar  lobes  6  and  7  of  the  vermis  cerebellum  were  used  for
comparison  (Fig.  1).  For  double  labeling,  images  from  the  same
confocal plane were taken. Alexa Fluor 647 signal (blue) was artificially
changed  to  red  color  to  show  S100β/GFAP  colocolization  in  merge
microphotographs (yellow) (Fig. 1 and 2).
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Thickness and number of Bergmann glia processes were measured on
confocal images of sagittal cerebellar slices. The number of radial glial
processes  for  100µm of  in  the  molecular  layer  (Sup.  Fig.  1A)  were
counted. The same 100µm line intensity profile was used to obtain the
distribution of GFAP fluorescence,  using the original  software of the
Olympus confocal microscope. Each glial process was shown as peak of
GFAP/Alexa  647  fluorescence  intensity.  We  counted  the  averaged
thickness  of  these  processes  in  each  image.  To  avoid  false  positive
enhancement  of  processes  thickness  we  used  cut-off threshold  for
recognition of the GFAP signal set to 10% of the maximal fluorescence
intensity.  To count the number of Bergmann glia cells,  we measured
anti-S100β positive circle- and oval-shaped signals in Purkinje cell layer.
To  avoid  over-  or  underestimation,  the  glial  cell  numbers  were
calculated by ceiling the ratio n=⌈ d
d '
⌉, where n is the cell number, d is
the length of S100β positive signal in μl of 50μM S100β in phosphate buffered saline (PBS) orm and d '=15 μmwhich we took for
characteristic diameter of an astrocyte. The approximate length of the
dendrites of the Purkinje cells was estimated from overall thickness of
the molecular layer (Sup. Fig. 1B), visualized using anti-calbindin/Alexa
488 staining.
2.6. Sholl analysis of Bergmann glia cells
Quantitative  morphological  analysis  was  performed  in  the  three-
dimensional (3D) mode. Using a confocal laser scanning microscope
(Olympus, Fluoview, FV10i)  anti-GFAP-labeled Bergmann glia was
scanned in Z-stacks (80–150 consecutive focal  planes at 0.25 μl of 50μM S100β in phosphate buffered saline (PBS) orm
interval). For Scholl analysis Z-stacks mages of soma and processes
of  Bergmann  glia  were  traced  on  focal  planes  using  ImageJ
software. We used the Sholl method of concentric circles using an
ImageJ regime (set of nested concentric spheres is centered on the
cell body, and the spheres increase in size by 10μl of 50μM S100β in phosphate buffered saline (PBS) orm radius) [27]. The
results of Sholl analysis showed length of processes and the number
of intersections per 10 μl of 50μM S100β in phosphate buffered saline (PBS) orm. 
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2.7. Statistical and mathematical analysis
Pooled data are expressed as the mean ± SEM. Statistical analyses
of differences between the groups were performed using the unpaired t-
test and Mann–Whitney U test. The influence of FC and TBOA on the
EPSC recovery was estimated with one-way ANOVA test.  Differences
were considered significant at p<0.05.
We estimated the dendritic and somatic capacitance by optimization
of the two-term exponential series to the current response curve to the
voltage step V step=10 V step=10 mV [28]:
I clamp( t )=V step(1 Rss−Ad τd e
− t
τd−A s τ s e
−
t
τs ) .
I clamp ( t )=V step ( 1Rss−Ad τd e−t / τd−A s τ se−t / τs)
to find the time constants τ i τ i. Here Rss=4  MΩR ss=4MΩ is the input
resistance and A i Ai are the free parameters. Indices d and s stand for
dendritic  and  somatic  components  respectively.  The  resulting
capacitance was then calculated as
Ci=
τ i
Rm
{i=d , s} C i=
τ i
Rm
{i=d , s }.  Rm
Rm is  the  membrane resistance.  Optimization  was  made in  ClampFit
10.7 software.
DSE was analyzed using dual exponential waveform equation (1).
DSE ( t )=100+A(e
−t
τ1 −e
−t
τ2){A=100aτ 1τ2τ1−τ2 } (1)
This  curve  is  convenient  for  the  prediction  of  the  conduction
changes in synapses [29]. It contains the parameters for both　decay
and recovery of EPSC separately during the DSE protocol. This model
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was fitted to the experimental data by the Nelder-Mead minimization of
the sum of squared residuals to find “A” – the maximum EPSC decrease
in percent of initial level, “𝜏1“and “𝜏2“ – the half-times for the EPSC to
reach the minimum and to recover to the initial 100%, respectively. The
parametric bootstrap technique was used to obtain the 95% confidence
intervals for the parameters 𝐴, 𝜏1, 𝜏2. This analysis was performed using
Python 3 package. 
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3. Results
3.1. Exogenous S100β alters morphology of Bergmann glia
2.5µl of 50µM S100β were injected in the cerebellar cortex to
induce  astrogliosis.  24  hours  later  widespread  distribution  of
S100β and increased GFAP expression in cerebellar cortex were
evident in lobules IV-VII (Fig. 1C compare to Fig. 1A, note that in
the normal brain immunofluorescent GFAP was poorly visible).
In microphotographs of S100β injected areas prominent GFAP
positive  striation was evident  (contrast  to PBS injected areas,
Fig. 1B and D). To analyze the morphology of Bergmann glia we
examined the number and thickness of  anti-GFAP-positive  glial
processes in the central part of molecular layer per 100μl of 50μM S100β in phosphate buffered saline (PBS) orm using
line  profile  function  (Sup.  Fig.  1A and  Fig.  2A  and  B).  The
average  cross-section  of  Bergmann  glia  processes  in  S100β
injected mice was increased to 3.6±0.1 µm, (364 processes from
17 areas of 3 mice) vs 2.8±0.1 µm, (358 processes from 11 areas
of 3 mice) in PBS injected mice, p =  1.25х10-13,  unpaired  t-test
(Fig.  2C).  The  number  of  processes  per  100μl of 50μM S100β in phosphate buffered saline (PBS) orm longitudinal
length  of  molecular  layer  in  S100β  injected  animals  was
significantly  decreased  compared  to  PBS  injected  animals
(21.4±2.0 vs 32.6±3.3, p = 0.013, t-test; Fig. 2D).The density of
Bergmann glia processes was also decreased in S100β injected
areas. We also measured the fraction of “GFAP-negative” space
in the central part of molecular layer per 100μl of 50μM S100β in phosphate buffered saline (PBS) orm using the same
line profile function. In S100β injected areas (17 areas of 3 mice)
it was increased to 24.0±4.5% compared with 8.1±1.6% in PBS-
injected areas (11 areas of 3 mice, p = 0.015; unpaired t-test;
Fig. 2E). Low Bergmann glia processes densityis mainly due to
the loss of some of these cells. Indeed, the number of anti-S100β-
labeled cell bodies per 100μl of 50μM S100β in phosphate buffered saline (PBS) orm longitudinal length of Purkinje cell
layer in S100β injected animals was significantly decreased in
comparison to PBS injected animals (9.1±0.4 vs 10.9±0.5, p =
0.007, unpaired t-test; Fig. 2F).
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Next,  we  studied  single  astrocyte morphology  using  Sholl
analysis (Sholl, 1953). On images of digitally traced Bergmann
glia processes (Fig. 3A) we analyzed the maximum number of
these processes per cell. This number was not changed in S100β
injected areas (4.9±1.2, n=12 from 3 animals) in comparison to
PBS injected  areas  (4.8±1.7,  n=10  from 3  animals,  p=0.648;
Mann–Whitney  U  test;  Fig.  3B).  Sholl  analysis  revealed  an
increase in the density of proximal processes in Bergmann glia
after S100β injections. Within 10μl of 50μM S100β in phosphate buffered saline (PBS) orm from soma in S100β injected
areas (12 areas of 3 mice) Bergmal glia had 3.3±0.3 processes,
while in PBS injected areas was 1.8±0.2 (p = 0.0002; 11 areas of
3 mice, Mann–Whitney U test; Fig. 3C.)
These data show that excessive extracellular S100β protein in the
cerebellar  cortex  leads  to  significant  changes  in  Bergmann  glia
morphology.
3.2. Extracellular S100β alters morphology of Purkinje cells
As  shown  above,  S100β  affects  glia  and  it  is  well-known  that
disturbances  in  glia  may  lead  to  neuronal  degeneration  [30–32].  In
addition,  S100β  could  have  a  direct  effect  on  Purkinje  cells.  We
examined the effect of  S100β on morphology of these neurons using
IHC and their physiological state using patch clamp. To estimate the
approximate  dendritic  length  of  PCs  cells  were  visualized  by  anti-
calbindin  staining  (Fig.  4A)  and  measured  the  thickness  of  the
molecular layer (Sup. Fig. 1B). S100β injections reduced it to 120.0±5.8
µm (n=12 areas from 3 mice) compared to 150.7±6.3 µm, n = 14 areas
from 3 mice in PBS injected mice (p=0,002, t-test; Fig. 4B).
Using patch clamp we estimated capacitance of dendrites and soma
after  subtraction  of  slow  capacitance  component  from  the  total
capacitance  of  PCs  (see  materials  and  methods).  Slow  component
reflects  predominantly  the  size  of  neuronal  dendrites.  We  found  a
significant difference between the two groups. The capacitances of PCs
dendrites in S100β injected mice were 359.4±37.5pF (n=33 cells from
8 mice) and 513.5±27.1pF (n = 52 cells from 10 mice) in PBS injected
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group.  (p=0,002,  t-test;  Fig.  3B).  The  capacitances  of  PCs  soma  in
S100β injected mice were 34.6±4.4pF (the same cells) and 61.7±5.6pF
(the same cells) in PBS injected group. (p=0,0003, t-test; Fig. 3C).
These data indicate that excessive extracellular S100β affects PCs
morphology, leading to the collapse of the soma and dendrites.
3.3. Extracellular S100β alters synaptic transmission in PFs and PCs
Astrocytes control removal of glutamate from the presynaptic space
[33–36].  Moreover,  astrocytic  secretion  of  S100β  protein  into  the
intercellular space leads to endocytosis of this protein by neurons and
evokes various effects such as chelation of cytoplasmic Ca2+ [20]. For
this  reason,  we  tested  whether  elevated  extracellular  S100β  affects
synaptic transmission in PF-PCs synapses. S100β  did not change the
PF-EPSCs amplitude (Sup. Fig. 2A).We suspected that S100β will affect
processes  highly  dependent  on  Ca2+ release,  such  as  presynaptic
glutamate secretion.  However,  we did not  see significant differences
between PPF ratio in PF-PC synapses of S100β and PBS injected mice.
The PPF ratio in S100β injected mice was 1.8±0.4, n=35 cells from 8
mice  vs  1.9±0.1,  n  =39  cells  from  9 mice  in  PBS  injected  mice
(p=0.722,  t-test;  Fig.  5A).  However,  S100β  dramatically  affected the
kinetics  of  PF-EPSCs.  While  there  was  no  statistically  significant
difference in the PF-EPSCs amplitude in mice injected with S100β and
PBS (Sup. Fig.  2A), the  rise time of PF-EPSC in S100β injected mice
was prolonged to  2.7±0.1ms (n=35 cells  from  8 mice),  compared to
2.3±0.1ms (n = 36 cells from 9 mice) in PBS injected mice (p=0.028, t-
test; Fig. 5B). 
To control for the potential effect of surgery per se, we analyzed this
parameter in sliced from naïve mice. No difference was found between
naïve and PBS injected groups (Sup. Fig. 3). 
In addition the decay time of PF-EPSC in S100β injected mice was
17.1±1.5ms (n=30 cells from 8 mice), while it increased to 21.6±1.5ms
(n = 37 cells from 9 mice) in PBS injected mice (p=0.04, t-test; Fig.
5C).
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These  results  demonstrate  that  the  excessive  extracellular
accumulation S100β protein mainly affects kinetics of PF-EPSC, which
most likely reflects changes glutamate removal from the synaptic cleft.
3.4.  Similarities  in  changes  in  synaptic  transmission  in  S100β-
injected mice and Ataxin1 mutant animals.
To look for similarities between SCA1 and consequences of S100β
injections we used KI mice with non-cell selective expression of mutant
Ataxin 1 [24]. Mice were used at 3 weeks of age which corresponds to
the early stage of neurodegenerative process. There was no statistically
significant difference in the PF-EPSCs amplitude recorded in the PCs of
SCA1 KI and WT mice (Sup. Fig. 2B). The PPF ratio in SCA1 KI mice
was 2.1±0.1, n=10 cells from 3 mice and 1.8±0.1, n = 8 cells from 3
mice in WT mice (p=0.012, unpaired t-test; Fig. 6A). PCs from SCA1 KI
mice have altered kinetics of PF-EPSCs. The average rise time of PF-
EPSC in SCA1 KI mice significantly increase to 3.0±0.2ms (n=10 cells
from 3 mice), compared to WT mice (2.3±0.2ms; n = 8 cells  from 3
mice; p=0.038, unpaired t-test; Fig. 6B). The differences in decay time
of  PF-EPSC  between  SCA1  KI  mice  and  WT  were  not  significant
(18.4±2.1ms, n=10 cells from 3 mice vs. 15.9±3.3ms, n = 8 cells from 3
mice; p=0.379, unpaired t-test; Fig. 6C).
3.5. Extracellular S100β alters endocannabinoid-dependent short term 
plasticity in PF-PC synapses
As mentioned above, we expected that S100β could affect processes
which are known to depend on the cytosolic concentration of Ca2+. One
of  such  processes  is  DSE,  which  is  evoked  by  the  membrane
depolarization.  Depolarization  leads  to  opening  of  voltage-gated
calcium channels (VGCC) and an increase in the intracellular Ca2+. Ca2+
triggers  endocannabinoid  release  from  the  postsynaptic  cell  with
consecutive activation of CB1 receptors  on the presynaptic terminal,
leading to a reduction in release of glutamate. We examined dynamic of
PF-EPSC amplitude after 5 sec of depolarization from -70 to 0 mV. The
stimulus  intensity  was  adjusted  to  reach  EPSC  amplitude  of
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approximately  150  pA  before  DSE  induction.  In  control  mice  DSE
protocol reduced EPSC by 67,3±3,5% (n = 11 cells from 4 mice) which
was similar to that in mice pre-injected with S100β (69,7±4,7%, n = 12
cells from  4 mice, p = 0,975,  unpaired t-test; Fig.  7A). However the
recovery of the PCs amplitude was significantly faster in S100β injected
mice.  50 sec after the challenge amplitude returned to  93.6±2.8% of
control,  compared  to  83.9±2.7%  in  PBS  injected  mice  (p  =  0.03,
unpaired t-test; Fig. 7A and B).
The  double  waveform  model  fit  (1)  confirmed  slowing  of  the
recovery  kinetics  by  S100β.  The  amplitude  reduction  in  the  DSE
protocol  was  not  significantly  different  in  S100β  injected  mice
compared  to  PBS  group:  45.5  (30.6,  63.6)%  vs  38.1  (31.8,  44.6)%
respectively. Using the fitting protocol we calculate that the half-time
for the recovery of the parameter (𝜏2) is significantly smaller in S100β
injected mice with 29.7 (21.0, 47.2) sec in comparison with 64.5 (52.0,
85.1) sec in PBS group, p<0.05.
These  results  demonstrate  that  excessive  extracellular  S100β
protein negatively affects DSE.
3.6. Effects of FC on PF-PC transmission and endocannabinoid short
term plasticity in PF-PC synapses
FC inhibits astrocytic metabolism and deprives these cells of energy,
this leading to an array of repercussions which ultimately undermine
functions  of  these  cells  [37].  Application  of  FC  led  to  a  strong
depression  of  PF-PC excitatory  transmission,  irrespective  of  whether
the tissue was exposed to S100β or not (Fig 8A and B). After 10 min
application the amplitude of PF-EPSC in S100β injected mice decreased
up to57.7±9.0% of control (n=7 cells from 4 mice, p=0.006, paired t-
test) and in PBS injected mice up to 64.4±9.9% of control (n = 7 cells
from 4 mice, p=0.014, paired t-test) (Fig. 8A and B). 10 min after FC
application averaged PF-EPSCs in S100β and PBS injected groups were
not different (unpaired t-test, p=0.65). The rise time of PF-EPSC in PBS
and S100β injected mice increased after FC treatment. In PBS group it
increased from 2.3±0.2ms to 2.7±0.2ms (n = 12 cells  from 4 mice,
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p=0.003, paired t-test; Fig. 8C) while in S100β group it increased from
2.4±0.3ms to 3.5±0.6ms (n = 10 cells from 3 mice, p=0.003, paired t-
test; Fig. 8C).
It was shown previously that astrocytes also contain CB1 receptors
and  could  modulate  the  synaptic  plasticity  [38].  CB1  receptors  in
astrocytes are coupled to Gq/11-proteins and trigger PLC activation [39]
and release such gliotransmitters as glutamate, ATP or d-serine [40].
This  phenomenon  is  SNARE-dependent  and  highly  sensitive  to  ATP
concentration which should be reduced by FC [41, 42]. However FC did
not affect expression of DSE. After FC application in PBS injected mice
DSE protocol reduced EPSC by 56,8±8,7% (n = 9 cells from 4 mice)
which was not statistically differ from what registered without FC in
S100β-injected mice (Fig. 8E) (p=0.317, unpaired t-test). However, this
comparison is compromised by the direct impact of FC on PF-induced
EPSCs and should be interpreted with care.
The double waveform model fit the changes of PF-EPSC amplitudes
after  depolarization  pulse  and  DSE  initiation.  Maximum  amplitudes
reduction was 51.92 (41.67, 81.41)% and 46.23 (33.28, 75.49)% for PBS
and S100β respectively.
However the recovery of the PCs amplitude was significantly slower
in FC treated PCs in slices from PBS-treated mice (Fig. 8F). 50 sec after
the  challenge,  it  returned  to  67.5±5.4%  of  control,  compared  to
untreated slices where it recovered to 83.9±2.7%, p = 0.025, unpaired
t-test; Fig. 8D-F. However, FC had hardly any effect on DSE protocol in
S100β  injected  mice  where  recovery  of  the  PCs  amplitude  was
81.4±7.6% of PF-EPSC amplitude at 50 sec post  challenge in FC vs
93.6±2.8% without FC; p = 0.181, unpaired t-test (Fig. 8D-F). 
Double waveform model fit also did not reveal significant changes
after the FC treatment.
3.7. Slowdown of glutamate uptake in Bergmann glia by TBOA leads to
alteration  of  PF-EPSC kinetic  but  does  not  change endocannabinoid
short term plasticity in PF-PC synapses
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90% of all glutamate uptakes in PF-PC synapses is due to excitatory
amino acid transporters EAAT1 and EAAT2, located on the membranes
of astrocytes [43, 44]. We suspected that shortening of PF-EPSC decay
time after S100β injection was due to facilitation of glutamate reuptake
through EAATs (Fig.  5C).  500μl of 50μM S100β in phosphate buffered saline (PBS) orM TBOA significantly increased decay
time of PF-EPSC in PBS and S100β injected mice. In PBS injected mice
decay time changed from 30.0±4.4to 39.2±6.3msec (n=16 cells from 4
mice,  p=0.039 paired  t-test, Fig.  9A).  Note  that  before  TBOA
application  decay  constants  were  different  between  S100β  and  PBS
injected  groups  (p=0.044,  one  way  ANOVA)  while  after  TBOA  they
reached approximately same values (p=0.64, one way ANOVA, Fig. 9A).
In  S100β  injected  mice  increase  was  even  more  dramatic,  from
19.2±2.7ms to 34.6±7.1ms (n=10 cells from 3 mice, p=0.031 paired t-
test). Application of nonselective EAAT blocker DL-TBOA 500μl of 50μM S100β in phosphate buffered saline (PBS) orM did not
significantly change PF-EPSC amplitudes and rise time in cerebellum of
both  PBS and S100β injected  mice  (data  not  shown).  TBOA did  not
affect  PPF  ratio  of  PF-EPSC  in  PBS  injected  mice  (1.86±0.1  vs
1.84±0.1;  n=16 cells  from  4 mice,  p=0.673 paired  t-test),  while  in
S100β  injected  mice  it  resulted  in  a  slight  but  significant  PPF ratio
reduction from 1.9±0.2 to 1.76±0.1 (n=10 cells from 3 mice, p=0.049
paired t-test, Fig. 9B).
We examined endocannabinoid short term plasticity in PF-PC synapses
after treatment of cerebellar slices with 500μl of 50μM S100β in phosphate buffered saline (PBS) orM TBOA. In PBS injected
mice DSE protocol was not affected by TBOA. EPSC were reduced by
59,2±5,4%;n = 15 cells from 4 mice) which was not statistically differ
from that before application (56.8±5.7%, p = 0,524, paired t-test). Also,
the recovery of the PCs amplitude was not affected by TBOA (Fig. 9C
and D). Neither did TBOA affect the outcome of DSE protocol in S100β
injected mice (74,8±9,6% reduction in TBOA, n = 11 cells from 4 mice
vs 73.6±8.8% without TBOA, p = 0,789, paired t-test). Also the recovery
of the PCs amplitude was unaffected by TBOA. The double waveform
model  yielded  in  the  PF-EPSC  amplitudes  reduction  during  DSE  as
45.71 (37.39, 56.75) % and 32.11 (14.73, 75.00) % for PBS and S100β
cells  respectively.  The  restoration  half-time  τ2 τ 2 was  69.28  (53.08,
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92.12) sec for PBS cells and 46.72 (18.68, 113.44) sec for S100β cells.
These results confirm that TBOA did not affect the outcome of the DSE
(Fig. 9 C and D).
These  results  demonstrate  that  the  slowdown  of  glutamate  uptake
predictably affects PF-EPSC decay time and does not change DSE.
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4. Discussion
It  was  shown  previously  that  activated  astrocytes  secrete  large
amounts  of  S100β  [11,  18].  PCs  absorb  glial  S100β  in  cytoplasmic
vacuoles, which leads to changes in their morphology and degeneration
[19, 45]. In SCA1 B05 tg mouse model, formation of S100β-containing
cytoplasmic vacuoles precedes accumulation of the mutant Ataxin 1 and
appearance  of  the  ataxic  phenotype [11].  Downregulation  of  S100β
rescues the neurological deficit; therefore, it has been argued that this
protein plays the central role in neurodegeneration [46]. We attempted
to mimic some of the features of SCA1 by injections of S100β. Mouse
S100β  was used in  order  to  avoid  an immune reaction  to  a  foreign
antigen. Using immunohystochemistry we found that the area of S100β
deposits  spread  much  further  than  the  actual  site  of  injection  and
covered  2-3  lobes  of  the  cerebellum.  The  maximal
immunochistochemical  signal  was  seen  in  lobes  5-7  (Fig.  1Сu).  For
imaging we adjusted the brightness of S100β/Alexa 488 fluorescence
signal so that to be able to image high concentration S100β without
saturation  of  the  system.  For  this  reason,  the  fluorescence  of  the
endogenous  S100β  in  control  mice  appears  low (Fig.  1A and B).  To
avoid false positive results when measuring the BG and PC morphology,
we used the  lobes  6  and 7  which  were not  directly  affected by  the
injection in all experiments. The excessive amount of S100β altered the
morphology of Bergmann glia. Reduction of Bergmann glia cell number
(Fig. 2B and F) and processes (Fig. 2D) was accompanied by thickening
of the processes (Fig. 2C) and sprouting of new processes in presomatic
areas (Fig. 3A and C).
The thickness of molecular layer correlates with the length of PC
dendritic tree [47]. To examine the approximate length of PCs dendrites
we  measured  thickness  of  molecular  layer  and  found  that  it  was
significantly reduced by S100β (Fig. 4A and B). Accordingly, soma and
dendritic capacitance of PCs also changed significantly (Fig. 4C). 
It  is  interesting  that  S100β  may  modulate  sodium  channels  in
neurons via Ca2+ chelation which affects neuronal sodium channels [48]
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which may result in bursting.  Kolta with coauthors showed that Ca2+
chelation  by  S100βin  intercellular  space  leads  to  Na+ currents
enhancement  and make them fire  action  potentials  in  bursts,  rather
than single AP. It is very likely open NMDA receptors and bring more
Ca2+ inside  the  neurons  [48].  Such a  mechanism could  lead to  Ca2+
overload  of  neurons  potentially  contributing  to  neurotoxicity  in  our
model.
Dendritic  tree  of  each PC has thousands of  synaptic  connections
with parallel fibers and 1-2 synapses with climbing fibers [49]. Hence
abnormality of dendritic morphology could lead to alteration of basic
synaptic transmission, such as EPSC. Our data suggest that S100β did
not affect presynaptic glutamate release because it did not significantly
change  PF EPSC amplitude  (Sup.  Fig.  2A)  and  PPF  ratio  (Fig.  5A).
Interestingly,  in PCs of 3 week-old SCA1 KI mice, where Ataxin-1 in
ubiquitously express, PPF ratio was increased in comparison to its WT
littermates  (Fig.  6A).  We  suspect  than  this  phenomenon  is  due  to
slowing of glutamate-glutamine cycle machinery because application of
FC leads to the same effect in PBS and S100β injected PCs (Fig. 8C).
We also show that PF-EPSC rise time is increased in 3 weeks old SCA1
KI mice (Fig. 6B). It is notable that in B05 mice that express mutant
Ataxin 1 selectively in PCs rise time was not changed at the same age
[50]. Therefore it is likely that changes caused by Ataxin 1 in other cells
such as Muller glia are responsible for this effect.  Injections of S100β
accelerated PF EPSCs decay time (Fig.  5C) which also points to the
involvement  of  the  Bergmann  glia,  which  plays  the  key  role  in
glutamate  uptake  [51,  52].  Application  of  TBOA  which  blocks  this
uptake,  ameliorated the  differences  between PF-EPSC decay  time of
PCs in PBS and S100β areas, consistent with this hypothesis (Fig. 9B).
At  the  same  time,  astrogliosis  and  neurodegeneration  is
characterized  by  suppression  of  EAAT1  and  EAAT2  function  and
accumulation of extracellular glutamate leading to excitotoxicity [52]. It
highly likely that with age the tendency for prolongation of PF-EPSC
decay time SCA1 KI mice (Fig. 6C) will increase and become significant.
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Therefore we acknowledge that our S100β injection model may not fully
reflect the complex pathological process in Bergmann glia.
Effect of S100β on short-term synaptic plasticity was assessed using
DSE. In DSE, strong depolarization leads to Ca2+-dependent release of
endocannabinoids  from  PCs,  which  retrogradely  activate  the  CB1
receptors  on  the  terminals  of  PFs  [53].  Activation  of  CB1  inhibits
glutamate  vesicular  release.  S100β  did  not  alter  PPF  ratio  which
suggests that as such the vesicular release machinery remained intact
(Fig.  5A). It is acknowledged that CB may also have direct effects on
glia  [54]  but  obviously  under  our  conditions  we  did  not  reveal  this
component.
Our  modelling  also  confirmed  that  while  DSE  protocol
depolarization was sufficient to decrease PF-EPSC amplitude up to 67-
69% of control in S100β and PBS injected mice (Fig. 7A) there was no
difference between these two groups. Thus, the induction phase of DSE
was not affected by S100 but the recovery after the initial depression
was  much  faster  in  S100β  injected  slices.  In  PBS  injected  animals
amplitude of PF-EPSC was fully restored to the control level at ~100
sec after depolarization, but it  only took 60-70 sec in S100β injected
group.  The  predicted  speed  of  restoration  by  the  double  waveform
fitting  (shown  by  solid  and  dashed  lines  on  Fig.7A)  resulted  in  the
significantly shorter recovery half-time in S100β group compared to the
PBS. Endocannabinoids are degraded by fatty acidamide hydrolase and
monoacylglycerol lipase. Faster recovery from DSE could be a result of
upregulation of these enzymes or simply indicate that S100β affected
the process of endocannabinoid release. A possible explanation for the
increased PF-EPSC recovery is an increase in extracellular glutamate
concentration.  In  astrocytes  CB  receptors  acts  as  antagonists  of
neuronal CB1 receptors and facilitate the neurotransmitter release [54,
41].  Possibly,  S100β-activated  astrocytes  release  more  glutamate  to
synaptic cleft after their CB receptors activation by DSE. In such We
used  FC  to  evoke  metabolic  “starvation”  of  astrocytes.  Interestingly
DSE (Fig. 8E) in PBS injected areas was sensitive to FC but in S100β it
was not. This suggests that the reactive astrocytes after S100β injection
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do  not  respond  to  endocannabinoids.  These  data  correlates  with
previous findings [54, 55]. 
In summary, elevated extracellular S100β leads to reorganization of
glia/neuron  morphology  and  disturbs  synaptic  transmission.  Our
findings  are  reminiscent  of  the  early  stage  of  a  neurodegenerative
process in cerebellar cortex such as seen from 3 old weeks SCA1 mice
[25]. The changes in PF-EPSC kinetics reported here were not seen in
non-cell  selective  SCA1  model  mice,  but  take  place  in  PC  selective
SCA1  model  mice,  where astrocytes are also affected by the mutant
Atxn1 [24 and  Fig. 6B]. We hope that our model will assist in better
understanding of  the role  of  glia  in  SCA1 and other  diseases which
affect cerebellum.
Figure Lеgends
Figure 1.Localization of S100β in mouse cerebellum.
(A) Confocal image of a cerebellar slice injected with PBS. Left: anti-
S100β. Right: anti-GFAP. Scale bar 1mm. 
(B) High power confocal  image of the zone indicated  on (A).Scale
bar 100μl of 50μM S100β in phosphate buffered saline (PBS) orm. 
(C)and (D) – as above but from mice pre-injected with S100β. Scale
bar in (C) is 1mm, in (D) 100μl of 50μM S100β in phosphate buffered saline (PBS) orm.
Figure  2.  S100β  alters  morphology  of  Bergmann  glia.
Microphotographs show anti-S100β and anti-GFAP immunoreactivity in
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injected  areas  from PBS (A)  and S100β  (B)  treated  mice. Scale  bar
50μl of 50μM S100β in phosphate buffered saline (PBS) orm. (C)Summary  graph  showing  the  thickness  of  Bergmann  glia
processes  in  μl of 50μM S100β in phosphate buffered saline (PBS) orm.  *** p<  0.001(D)  In  a  comparison  to  PBS  injected
areas, there were significantly fewer Bergmann glia processes per 100μl of 50μM S100β in phosphate buffered saline (PBS) or
in S100β injected areas. * p< 0.05 (E) Bergmann glia’s processes were
more  sparse  in  S100β  injected  areas.  *  p<  0.05  (F)  Reduction  in
Bergmann glia cell bodies caused by S100β. ** p< 0.01
Figure  3.Analysis  of  Bergmann glia  process  morphology  in
PBS  and  S100β-injected mice.injected  mice. (A)  White  and  black
microphotographs  of  anti-GFAP-labeled  areas  of  cerebellar  cortex
injected with PBS (left images) and S100β (right images). Light images
contain  digitally  traced  Bergmann  glia  processes  generated  using
ImageJ  software.  Arrows  show  the  proximal  processes  which  were
found  more  often  in  S100β  injected  areas.  Scale  bar  50μm. (B)m.  (B)
Maximum number of processes per Bergmann glia cell did not change
between  PBS  and  S100β-injected  areas.  (C)  Sholl  analysis  for  PBS-
(open circles) and S100β-injected (closed circles) Bergmann glia cells
(number of intersections per 10μm. (B)m of processes length).  ** p< 0.01,
***p<0.001
Figure  4.S100β  alters  the  PCs  morphology  of  mouse
cerebellum.(A)  Comparison  of  immunoreactivity  to  anti-
calbindin (PCs  marker),  and  anti-GFAP in  injected  areas  with
PBS (upper panel) and S100β (lower panel). The molecular layer
selected  by  white  broken  lines.  Scale  bar  50μl of 50μM S100β in phosphate buffered saline (PBS) orm.  (B)  In
comparison  to  PBS  injected  areas,  the  molecular  layer  was
significantly  thinner (79,6%)  in S100β injected areas.  (C) In a
comparison  to  PBS  injected  areas  the  capacitance  of  PCs
dendrites and soma measured by voltage-clamp was significantly
smaller in S100β injected areas. ** p< 0.01,**<0.01, ***<0.001.
Figure  5.S100β  alters  PCs  electrophysiological
properties(A) The summary graph shows the average PFF ratio
(2nd amplitude /1st amplitude EPSC) in PCs from PBS and S100β
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injected  areas,  no  significant  differences  found.  Below  –
representative  traces  of  PF-EPSCs  (B) The  summary  graph
shows the average rise time of PF-EPSCs in PCs from PBS and
S100β injected areas. In comparison to PBS injected areas,  rise
time  was  significantly  longer  in  S100β  injected  areas.
Representative  traces  of  PF-EPSCs  are  shown  above.  (C)  In
comparison  to  PBS  injected  areas,  the  decay  time  was
significantly  longer  in  S100β  injected  areas.  The  represented
traces of PF-EPSCs are above.* p< 0.05.
Figure 6.Electrophysiological properties of PCs are altered in 3
weeks old non-cell selective SCA1 model mice. (A) Average PFF
ratio (2nd amplitude /1st amplitude EPSC) in PCs from WT and
SCA1  KI  mice.  In  comparison  to  WT  PCs,  the  PPF  ratio
significantly  increased in  SCA1 KI mice.  Above representative
traces of PF-EPSCs. (B) The average rise time of PF-EPSCs in
PCs from WT and SCA1 KI mice. In comparison to WT PCs, the
rise  time  was  significantly  longer  in  SCA1  KI  animals.
Representative traces of PF-EPSCs are above. (C) Average decay
time of PF-EPSCs in PCs from PBS and S100β injected areas. No
significant differences. The represented traces of PF-EPSCs are
above. * p< 0.05.
Figure  7. S100β  disrupts  the  DSE  at  PF-PC  synapses.  (A)
Average time course diagram of PF-EPSC amplitudes before and
after  depolarization.  The  amplitudes  of  PF-EPSC  were
normalized to values before depolarization. The numbers (n) of
tested PCs and animals (PCs/animals) are indicated in the graph.
Dotted and black lines indicate the double waveform model fit
for  PBS  and  S100β  injected  groups,  respectively.  Above  -
representative PF-EPSC traces from PCs from PBS and S100β-
injected mice are above the diagram. Time points: before (1) and
50 sec after (2) depolarization. (B) PF-EPSC amplitudes 50 sec
after depolarization.  In comparison to PBS injected areas,  the
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PF-EPSC amplitude was significantly  bigger in  S100β injected
areas.* p< 0.05.
Figure  8.  Downregulation  of  astrocytic  function  by  FC
affects  amplitude  and  kinetics  of  PF-EPSC  in  PF-PC
synapses. (A) Time course of PF-EPSC amplitudes before and
after 50μl of 50μM S100β in phosphate buffered saline (PBS) orM FC application. (B) Averaged PF-EPSC amplitudes 10
min after  FC application.  Effect  of  FC was approximately  the
same  in  S100β  ad  PBS  injected  slices.  (C)  FC  changed
significantly  PF-EPSC  rise  time  in  PBS-injected  animals,  and
slightly increased it after administration of S100β ** p< 0.01,  Ɨ
p<0.05. (D) Representative PF-EPSC traces elicited in PCs from
PBS  and  S100β-injected  mice  are  above  the  diagram.  Time
points:  before  (1)  and  50 sec  after (2)  depolarization.  (E)  PF-
EPSC amplitudes 50 sec after depolarization. In comparison to
PBS  injected  areas,  the  PF-EPSC  amplitude  was  significantly
bigger  in  S100β  injected  areas.*  p<  0.05  Bergmann  glia
suppression by FC leads to significant DSE enchantment in PBS
injected  PCs.  Ɨ<0.05.  (F)  Average  time  course  of  PF-EPSCs
before and after depolarization in slices treated with 50μl of 50μM S100β in phosphate buffered saline (PBS) orM FC.
Dotted and black lines  indicate the double waveform model fit
for PBS and S100β injected groups, respectively. 
Figure 9. Inhibition of glutamate uptake by TBOA alters PF-EPSC
kinetic but does not affect endocannabinoid-mediated short term
plasticity. 
(B) (A) TBOA prolongs EPSP in PBS and S100β-injected tissues (҂
p<0.05). Note that the baseline tau was reduced after S100β
application but the effect of TBOA was comparable to control.
TBOA  had  minimal  effect  on  PPF  ratio  only  in  slices  from
S100β injected animals. * p< 0.05.
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(C) Average diagram of PF-EPSC amplitudes before and 30 sec
after depolarization. Application of TBOA marked by red line. The
amplitudes  of  PF-EPSC  were  normalized  to  values  before
depolarization.*  p<  0.05.  (D)  Representative  PF-EPSC  traces
elicited in PCs from PBS and S100β-injected mice are above the
diagram.  Time  points:  before  (1)  and  30  sec  after  (2)
depolarization. Average time course of PF-EPSCs before and after
depolarization in slices treated with TBOA. Dotted and black lines
indicate  the  double  waveform  model  fit  for PBS  and  S100β
injected groups, respectively.
Supplementary Materials:
Supplementary Figure  1.  (A)  Confocal  image  of  S100β-injected  area
(anti-S100β  and  anti-GFAP  staining).  The  line  with  two  arrowheads
illustrates  the  100μl of 50μM S100β in phosphate buffered saline (PBS) orm length where the  parameters  of  Bergman glia
processes were evaluated (B) Confocal image to illustrate staining with
anti-Calbindin and anti-GFAP antibodies. The line with two arrowheads
illustrates the thickness of cerebellar molecular layer.
Figure S2: Electrophysiological characteristics of PCs (A) The summary
graph shows the average PF-EPSC amplitudes in PCs from PBS and
S100β injected areas. There was no significant differences between the
two groups. The numbers (n) of tested PCs and animals (PCs/animals)
are  indicated  in  the  graph.  (B)  Average PF-EPSC amplitudes  in  PCs
from  3  weeks  old  WT  and  SAC1  KI  mice.  Differences  between  the
groups were not significant. The numbers (n) of tested PCs and animals
(PCs/animals) are indicated in the graph.
Figure S3: PBS injections do not alter decay time of PF-EPSC.
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